Genmab A/S (NASDAQ:GMAB) Shares Sold by Vestmark Advisory Solutions Inc.

Posted by on Apr 1st, 2023

Vestmark Advisory Solutions Inc. reduced its position in Genmab A/S (NASDAQ:GMAB – Get Rating) by 16.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,999 shares of the company’s stock after selling 9,020 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Genmab A/S were worth $1,907,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sequoia Financial Advisors LLC acquired a new position in shares of Genmab A/S during the fourth quarter worth approximately $869,000. Ronald Blue Trust Inc. lifted its holdings in shares of Genmab A/S by 309.8% in the fourth quarter. Ronald Blue Trust Inc. now owns 840 shares of the company’s stock valued at $27,000 after purchasing an additional 635 shares in the last quarter. Harbour Capital Advisors LLC purchased a new stake in shares of Genmab A/S during the fourth quarter worth $278,000. Fulton Bank N.A. purchased a new stake in shares of Genmab A/S during the fourth quarter worth $239,000. Finally, FourThought Financial LLC raised its holdings in shares of Genmab A/S by 49.8% during the third quarter. FourThought Financial LLC now owns 1,227 shares of the company’s stock worth $39,000 after acquiring an additional 408 shares in the last quarter. 6.73% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GMAB. JPMorgan Chase & Co. increased their price objective on Genmab A/S from 3,450.00 to 3,600.00 and gave the stock an “overweight” rating in a report on Tuesday, January 3rd. Danske upgraded Genmab A/S from a “hold” rating to a “buy” rating in a report on Thursday, February 23rd. Citigroup lowered Genmab A/S from a “buy” rating to a “neutral” rating in a report on Tuesday, December 20th. Finally, SVB Leerink increased their target price on shares of Genmab A/S from $33.00 to $36.00 and gave the stock a “market perform” rating in a research report on Monday, February 6th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of “Hold” and a consensus target price of $632.62.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $37.76 on Friday. The company has a market cap of $24.91 billion, a P/E ratio of 32.27, a P/E/G ratio of 1.60 and a beta of 0.97. The stock’s 50-day moving average is $37.74 and its 200-day moving average is $39.33. Genmab A/S has a 52-week low of $26.19 and a 52-week high of $47.50.

Genmab A/S Profile

(Get Rating)

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.

Read More

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB – Get Rating).

Institutional Ownership by Quarter for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.